MCP-1-2518 A>G and CCR2 V64I polymorphisms in Turkish patients with lung cancer

In the current study, we aimed to investigate the possible role of mcp-1 -2518 a>g and cc chemokine receptor 2 (ccr2) v64i polymorphisms in patients with lung cancer. sixty-five patients with lung cancer (57 with nsclc and 8 with sclc) and 57 healthy controls were enrolled. polymerase chain reactionrestriction fragment length polymorphism (pcr-rflp) method was used. genotype distribution of monocyte chemoattractant protein 1 (mcp-1) -2518 a>g polymorphism in lung cancer patients was as follows: 30 for aa, 30 for ag and 5 for gg genotype. frequency of minor g allele in patients and controls were found as 30.8% and 23.7%, respectively. in patients, genotype distribution of ccr2 v64i polymorphism was as follows: 47 for gg, 16 for ga, and 2 for aa. frequency of minor a allele was found in patients and controls as 15.4% and 19.2%, respectively. genotype distribution and allele frequencies of mcp-1 and ccr2 polymorphism were not statistically different between patients and controls (p values >0.05 for both polymorphisms). in lung cancer patients, there was no significant association between smoking status and mcp-1 and ccr2 polymorphisms. similarly, no significant association was found between distant organ metastasis and both gene polymorphisms. our findings suggest that mcp-1 -2518 a>g and ccr2 v64i polymorphisms are not associated with genetic susceptibility to lung cancer and lung cancer metastasis.